politics
First human GLP-1 gene therapy trial gets green light
Key takeaways
- Fractyl Health received clinical trial authorization in the Netherlands this week to begin a first-in-human study of RJVA-001in patients with obesity and Type 2 diabetes.
- GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain, Dr.
- RJVA-001 takes a different path: a potential one-time, pancreas-targeted gene therapy designed to enable the body to produce GLP-1 in response to meals: physiology, not pharmacology, Rajagopalan added.
Why this matters: political developments that affect policy direction and public trust.
Fractyl Health received clinical trial authorization in the Netherlands this week to begin a first-in-human study of RJVA-001in patients with obesity and Type 2 diabetes.
GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain, Dr. Harith Rajagopalan, CEO of Fractyl Health, said.
RJVA-001 takes a different path: a potential one-time, pancreas-targeted gene therapy designed to enable the body to produce GLP-1 in response to meals: physiology, not pharmacology, Rajagopalan added.
Article preview — originally published by The Hill. Full story at the source.
Read full story on The Hill →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from The Hill alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop